Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s Disease
Key Highlights
- ➤617 TAUKLARIFY PET scans evaluated across two pivotal Phase 3 studies
- ➤All five independent readers met co-primary sensitivity and specificity endpoints
- ➤CE-20-01 sensitivity ranged 79.9%-88.5%; specificity reached 97.9%-99.3%
- ➤CE-23-01 sensitivity ranged 68.2%-82.4%; specificity reached 93.5%-99.4%
- ➤Pooled safety analysis found florquinitau F 18 generally well tolerated
Expert Statements
Christopher Rowe, Director of Molecular Imaging Research at Austin Health
“Tau neurofibrillary tangles are among the pathological features most closely associated with cognitive decline and prognosis in Alzheimer’s disease, making their reliable detection especially important in earlier clinical stages.”
Christopher Rowe, Director of Molecular Imaging Research at Austin Health
“I am encouraged by the strength and consistency of these findings across both Phase 3 studies which clearly show how tau-targeted PET imaging can help identify tau pathology in people with Alzheimer’s disease, including those in earlier clinical stages of the disease.”
Christopher Rowe, Director of Molecular Imaging Research at Austin Health
“These findings may give clinicians a clearer view of disease progression at a time when that information may be particularly valuable.”
Ludger Dinkelborg, Head of Research & Development at Lantheus
“What makes these studies particularly noteworthy is the use of a prospectively defined clinical radiological reference standard informed by extensive neuropathological evidence.”
Ludger Dinkelborg, Head of Research & Development at Lantheus
“This innovative approach allowed the inclusion of images from individuals at the early stages of symptomatic Alzheimer’s disease, and through a rigorous evaluation, demonstrated that the diagnostic performance of TAUKLARIFY PET scans in this population was highly consistent across two independent pivotal studies.”
Ludger Dinkelborg, Head of Research & Development at Lantheus
“These findings reinforce how tau imaging, alongside amyloid beta imaging, may provide complementary insights that help researchers better characterize Alzheimer’s disease and advance hope for physicians and patients fighting against this disease.”
BEDFORD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced results from two pivotal Phase 3 studies evaluating the diagnostic performance of the TAUKLARIFY™ (florquinitau F 18 injection) PET imaging, also referred to as MK-6240, which supported FDA use in adults with cognitive impairment being evaluated for Alzheimer's disease to identify patients with neurofibrillary tangle (NFT) pathology. The safety and effectiveness of TAUKLARIFY have not been established for the evaluation of non-Alzheimer’s disease tauopathies. In both studies, which included individuals with early symptomatic disease, all five independent readers met the prespecified co-primary endpoints of sensitivity and specificity, demonstrating consistent diagnostic performance and high inter-reader agreement. Results were presented today at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 meeting in Boston, Massachusetts.
Get started
Create a free account to read the full story.
